CCR Antagonist

CCR Antagonists (105):

Cat. No.	Product Name	Effect	Purity

HY-B0155B

Vicriviroc malate	Antagonist
Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.

HY-148232

BAY-3153	Antagonist
BAY-3153 is a selective CCR1 (C-C motif chemokine receptor 1) antagonist (human IC₅₀=3 nM; rat IC₅₀=11 nM; mice IC₅₀=81 nM).

HY-153669

SB-649701	Antagonist
SB-649701 is a potent human CCR8 antagonist, with a pIC₅₀ of 7.7. AZ084 can be used for the research of asthma.

HY-172161

CCR6 antagonist 2	Antagonist
CCR6 antagonist 2 (Compound 20c) is the antagonist for CCR6 with a K_i of 1.1 nM. CCR6 antagonist 2 inhibits CCL20-induced calcium ion influx (IC₅₀ = 4.9 nM), inhibits the chemotactic migration of CCR6+ T cells (IC₅₀ = 190 nM).

HY-152131

CCR5 antagonist 2	Antagonist
CCR5 antagonist 2 (Compound 25) is a CCR5 antagonist with an IC₅₀ of 8.34 nM. CCR5 antagonist 2 shows broad-spectrum anti-HIV-1 activities.

HY-108432

BMS-741672	Antagonist
BMS-741672 is a selective and orally active CCR2 antagonist with an IC₅₀ of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5.

HY-100261

CCR5 antagonist 1	Antagonist
CCR5 antagonist 1 is a CCR5 antagonist which can inhibit HIV replication extracted from WO 2004054974 A2.

HY-119293A

K777 tosylate	Antagonist
K777 tosylate is a potent, orally active and irreversible cysteine protease inhibitor. K777 tosylate is also a potent CYP3A4 inhibitor with an IC₅₀ of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 tosylate irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 tosylate is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 tosylate inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively.

HY-160998

YM-344031	Antagonist
YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC₅₀ of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca^[2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model.

HY-110132

JNJ-27141491	Antagonist
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2.

HY-124668

CCR1 antagonist 12	Antagonist
CCR1 antagonist 12 (Compound 12) is an antagonist for CCR1 with IC₅₀ of 3 nM for human CCR1. CCR1 antagonist 12 inhibits CCL3-induced transwell chemotaxis with an IC₅₀ of 0.009 µM. CCR1 antagonist 12 exhibits good pharmacokinetic characters in rats model.

HY-N10397

Maceneolignan H	Antagonist
Maceneolignan H (Compound 8) is a neolignane compound isolated from the arils of Myristica fragrans. Maceneolignan H is a selective CCR3 antagonist (EC₅₀ = 1.4 μM). Maceneolignan H has the potential for the research of allergic diseases.

HY-120629

BMS-639623	Antagonist
BMS-639623 is a potent and orally activeCCR3 antagonist with an IC₅₀ of 0.3 nM. BMS-639623 picomolar inhibition potency against eosinophil chemotaxis (IC₅₀=38 pM). BMS-639623 can be used for the research of asthma.

HY-119658

PF-4178903	Antagonist
PF-4178903 (INCB10820) is an orally active, potent dual CCR2 and CCR5 antagonist with IC₅₀ values of 3 nM and 5.3 nM, respectively. PF-4178903 is promising for research of chronic inflammatory and autoimmune diseases.

HY-13004S

Maraviroc-d₆	Antagonist
Maraviroc-d₆ (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV[1][2].

HY-103360A

cis-J-113863	Antagonist
cis-J-113863 is a competitive chemokine receptor 1 (CCR1) antagonist, with IC₅₀ values of 0.9 and 5.8 nM for human and mouse CCR1 receptors, respectively.

HY-162505

SQA1	Antagonist
SQA1, a squaramide (SQA) derivative, is a CCR6 antagonist with a K_d of 250 nM. SQA1 is also a CXCR2 inhibitor. The intracellular pocket occupied by SQA1 overlaps with the G protein binding site and stabilizes the closed conformation of the intracellular pocket.

HY-14231

CCR5 antagonist 5	Antagonist
CCR5 antagonist 5 (compound example 11) is a CCR5 antagonist. CCR5 antagonist 5 has the potential to study inflammation and immunity and viral (such as HIV) infection.

HY-103360B

trans-J-113863	Antagonist
trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC₅₀ of 9.57 and 93.8 nM,respectively.

HY-160647

CCR8 antagonist 3	Antagonist
CCR8 antagonist 3 (compound 2) is a CCR8 antagonist with an IC₅₀ value of 0.062 µM. CCR8 antagonist 3 shows human microsomal stability.

Name
Email *

	Sorry, but the email address you supplied was invalid.